Precision BioSciences
Precision BioSciences is dedicated to improving life (DTIL) through the application of its pioneering, proprietary genome editing platform, ARCUS. Precision leverages ARCUS to develop product candidates in allogeneic (off-the-shelf) CAR T immunotherapy, in vivo gene correction, and food. Its lead clinical programs are currently in the allogeneic CAR T space with the most advanced product candidate being PBCAR0191, an allogeneic anti-CD19 CAR T therapy candidate currently being evaluated in collaboration with Servier in adult patients with relapsed or refractory NHL or B-ALL. Precision initiated dosing of subjects in a Phase 1/2a clinical trial of PBCAR0191 in April 2019, which continues to progress as planned. In September 2019, Precision announced FDA clearance of its IND for PBCAR20A, the company’s second and wholly-owned allogeneic CAR T candidate targeting CD20. Precision expects to file an IND for its wholly-owned BCMA targeted allogeneic CAR T candidate in 2020.